Talis Biomedical Corporation (TLIS) has an overall financial health rating of C+ with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2025-06-27.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-06-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-06-25 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-06-24 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-06-18 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-06-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-06-04 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-06-02 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-05-29 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-05-16 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-05-14 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-05-13 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-04-21 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
